Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy

Yu Cheng, Ramin Morshed, Shih Hsun Cheng, Alex Tobias, Brenda Auffinger, Derek A. Wainwright, Lingjiao Zhang, Catherine Yunis, Yu Han, Chin Tu Chen*, Leu Wei Lo, Karen S. Aboody, Atique U. Ahmed, Maciej S. Lesniak

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


A 3-step glioblastoma-tropic delivery and therapy method using nanoparticle programmed self-destructive neural stem cells (NSCs) is demonstrated in vivo: 1) FDA-approved NSCs for clinical trials are loaded with pH-sensitive MSN-Dox; 2) the nanoparticle conjugates provide a delayed drug-releasing mechanism and allow for NSC migration towards a distant tumor site; 3) NSCs eventually undergo cell death and release impregnated MSN-Dox, which subsequently induces toxicity towards surrounding glioma cells.

Original languageEnglish (US)
Pages (from-to)4123-4129
Number of pages7
Issue number24
StatePublished - Dec 20 2013


  • doxorubicin
  • drug delivery
  • glioblastoma
  • glioma
  • mesoporous silica nanoparticles
  • neural stem cells
  • targeted delivery

ASJC Scopus subject areas

  • Biotechnology
  • Biomaterials
  • Chemistry(all)
  • Materials Science(all)

Fingerprint Dive into the research topics of 'Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy'. Together they form a unique fingerprint.

Cite this